SETD1A and schizophrenia: The realization of precision medicine, such as gene therapy, for specific genetic diseases frequently comorbid with schizophrenia (e.g., 22q11.2 deletion or SETD1A haploinsufficiency syndrome) leveraging the observations in studies of these models might be the achievable goal within the next decade.